AstraZeneca Pharma Receives CDSCO Approval to Import and Sell Benralizumab for HES Patients Aged 12+

Market snapshot: AstraZeneca Pharma India Limited has secured regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute Benralizumab (30 mg/mL solution for injection) in pre-filled syringes. The therapy is approved as an additional indication for the treatment of patients aged 12 years and older suffering from Hypereosinophilic Syndrome (HES) without an identifiable non-haematologic secondary cause.

Data Snapshot

• CDSCO granted import and marketing permission for Benralizumab 30 mg/mL solution for injection in pre-filled syringe on July 15, 2026.
• AstraZeneca Pharma India reported a 32.6% rise in total revenue from operations to ₹2,275.58 crore for the fiscal year ended March 31, 2026.
• Oncology therapeutic segment led AstraZeneca's FY26 sales, contributing ₹1,610 crore, which represents a 43.1% YoY growth.

What's Changed

• Prior to this approval, Benralizumab (Fasenra) was approved in India by CDSCO on May 26, 2026, for an additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The new approval expands the patient demographic down to age 12 and extends the therapeutic scope to Hypereosinophilic Syndrome (HES).

Key Takeaways

• Expanded Market Footprint: The CDSCO approval enables AstraZeneca to target the rare disease and specialized respiratory market segments in India for patients aged 12 and above.
• Rapid Regulatory Momentum: This represents the latest in a series of regulatory clearances for AstraZeneca India in 2026, building on approvals for Trastuzumab deruxtecan (Enhertu) in June 2026 and Acalabrutinib (Calquence) in April 2026.
• High-Value Portfolio Expansion: Adding HES to the indications for Benralizumab leverages AstraZeneca's existing specialty commercial infrastructure in India, driving higher operating leverage.

SAHI Perspective

This approval demonstrates AstraZeneca India's strong commitment to accelerating its global pipeline in the domestic market. By expanding the indications for Benralizumab to HES and lowering the treatable age to 12, AstraZeneca is addressing a significant unmet clinical need in rare eosinophilic disorders. Strategically, this reinforces the company’s pivot towards high-margin biopharmaceuticals and rare disease therapies, which stood at ₹524 crore and ₹21 crore respectively in FY26.

Market Implications

The approval is highly positive for AstraZeneca Pharma India. It adds a premium, high-margin biologic to its active commercial portfolio, strengthening its positioning in the immunology and rare disease spaces. Historically, product launches of this nature have driven robust specialty sales, which will help mitigate the impact of the ongoing exit from its Bangalore manufacturing site and support long-term top-line growth.

Trading Signals

Market Bias: Bullish

AstraZeneca's continuous stream of regulatory approvals—capped by this new high-margin CDSCO clearance for Benralizumab—reinforces its robust long-term specialty growth. This follows an impressive FY26 revenue growth of 32.6% to ₹2,275.58 crore.

Overweight: Healthcare, Pharmaceuticals, Biotechnology

Trigger Factors:

• Commercial launch timeline and pricing structure of Benralizumab for HES in India
• Therapeutic segment revenue growth in upcoming quarterly results
• Further approvals from the pipeline of 11+ regulatory filings submitted in India

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian biopharmaceutical landscape is witnessing a structural shift towards targeted biologics and monoclonal antibodies. As regulatory agencies like CDSCO expedite approvals for rare and severe disease therapies under local clinical trial waiver frameworks, multinational pharmaceutical companies are positioned to command premium pricing. The severe asthma and eosinophilic therapy market globally is expanding rapidly, and AstraZeneca's early-mover advantage in multiple indications for Benralizumab in India establishes a strong competitive moat.

Key Risks to Watch

• High Treatment Costs: Biologic therapies like Benralizumab carry substantial price tags, which may limit initial adoption to tier-1 cities and private insurance-covered patient pools.
• Regulatory Delays: Any subsequent delay in securing local pricing approvals or state-level commercialization permissions could slow the initial launch trajectory.
• Executive Transitions: Recent senior management changes, including the departure of the Oncology Business Unit Director and Operations Site Lead in June 2026, could cause short-term execution friction.

Recent Developments

On June 10, 2026, AstraZeneca received CDSCO permission to import and market Trastuzumab deruxtecan (Enhertu) for the first-line treatment of adult patients with HER2-positive breast cancer. Additionally, on May 26, 2026, the company secured CDSCO approval for Benralizumab for relapsing or refractory EGPA and announced its FY26 annual results with a 32.6% rise in revenue to ₹2,275.58 crore.

Closing Insight

AstraZeneca India's systematic expansion of its specialty biologics pipeline represents a compelling growth driver. By securing back-to-back approvals for Benralizumab across multiple high-value rare disease indications, the company is successfully transitioning its domestic business model towards premium specialty care, insulating its margins from traditional generic pricing pressures.

High Performance Trading with SAHI.